A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate

BACKGROUND

Absorption of EPA and DHA from Omega-3-acid ethyl ester (EE) concentrate supplements occurs most efficiently when taken in context of a fatty meal; adequate fat intake is required to release bile salts that emulsify and pancreatic enzymes that digest omega-3-containing lipids in the intestine. Current guidelines recommend reduction in fat intake and therefore there is a need to optimize the absorption of Omega-3 in those consuming low-fat or no-fat meals. To this end, BASF has developed an Absorption Acceleration Technology, a novel self-micro-emulsifying delivery system (SMEDS) formulation of highly concentrated Omega-3-acid EE which enables rapid emulsification and microdroplet formation upon entering the aqueous environment of the gut therefore enhances the absorption.

METHODS

Two separate single dose, crossover studies were conducted to determine the relative bioavailability of omega-3-acid EE concentrate, either as a novel SMEDS formulation (PRF-021) or as control, in healthy fasted male and female adults at two dose levels (Study 1 "low dose": 630 mg EPA + DHA in PRF-021 vs. 840 mg EPA + DHA in control; Study 2 "high dose": 1680 mg EPA + DHA in PRF-021 vs. 3360 mg EPA + DHA in control). Blood samples were collected immediately before supplementation and at defined time intervals for 48 h. Plasma concentration of total EPA and DHA were determined for pharmacokinetic analysis, area under the curve (AUC) and maximum observed concentration (Cmax) was determined.

RESULTS

Total EPA plus DHA absorption from SMEDS formulation PRF-021 were 6.4 and 11.5 times higher compared to control in low- and high-dose studies respectively, determined as the ratio of baseline corrected, dose normalized AUC0-24h of PRF-021 over that of control. EPA and DHA individually showed differing levels of enhancement: the AUC0-24h ratio for EPA was 23.8 and 25.7 in low and high dose studies, respectively, and the AUC0-24h ratio for DHA was 3.6 and 5.6 in low and high dose studies, respectively. Cmax was also increased for both EPA and DHA 2.7- to 9.2-fold.

CONCLUSION

PRF-021 is a novel SMEDS formulation of Omega-3-acid EE demonstrating a marked improvement in absorption of a single dose of EPA and DHA EE under fasted conditions. This allows adequate absorption of Omega-3 from the supplement without the requirement of a high-fat meal.

Current legislation governing clinical waste disposal

The paper considers UK and EC Legislation regulating clinical waste disposal. The legal definition of clinical waste is distinguished from both 'health care waste' and 'infectious waste'. Waste can be pre-treated so as to enable it to be disposed of through the normal waste stream. The legislation is looked at by reference to (i) production and storage; (ii) handling and transportation; and (iii) disposal. It is vitally important to draw up a waste management strategy. Effective segregation at source is a key factor in the waste management strategy and it will enable hospital authorities to make economic savings in waste disposal costs. The Paper considers the Duty of Care under the Environmental Protection Act 1990 and stresses the obligation on each person in the waste disposal chain to discharge the Duty. Landfilling as a method of disposal is discouraged except for waste where no possibility of infection arises. There are problems with hospital incinerators meeting modern emission standards. Requirements for licensing new incinerators are examined. The new Waste Management Licensing Regulations 1994 require applications for Waste Management Licenses to demonstrate technical and financial competence as 'fit and proper persons'. The Paper concludes by examining penalties for breach of regulatory provisions.